Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 116.63% | -42.75% | -70.81% | -66.36% | -73.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 116.63% | -42.75% | -70.81% | -66.36% | -73.71% |
| Cost of Revenue | 159.62% | -64.83% | -134.60% | -136.40% | -138.81% |
| Gross Profit | 34.29% | -39.08% | -47.41% | -36.92% | -47.45% |
| SG&A Expenses | 42.63% | 68.55% | 46.94% | 83.52% | 27.84% |
| Depreciation & Amortization | 35.93% | 62.40% | 76.79% | 63.40% | 50.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.97% | 57.65% | 22.36% | 35.57% | 5.09% |
| Operating Income | -51.85% | -236.93% | -327.43% | -400.43% | -541.36% |
| Income Before Tax | -52.52% | -155.94% | -188.86% | -207.82% | -191.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -52.52% | -155.94% | -188.86% | -207.82% | -191.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.52% | -155.94% | -188.86% | -207.82% | -191.27% |
| EBIT | -51.85% | -236.93% | -327.43% | -400.43% | -541.36% |
| EBITDA | -56.02% | -257.47% | -440.02% | -568.95% | -1,114.49% |
| EPS Basic | -33.03% | -129.41% | -157.89% | -175.47% | -172.50% |
| Normalized Basic EPS | -33.33% | -128.57% | -157.14% | -169.70% | -164.00% |
| EPS Diluted | -33.03% | -129.41% | -157.89% | -175.47% | -172.50% |
| Normalized Diluted EPS | -33.33% | -128.57% | -157.14% | -169.70% | -164.00% |
| Average Basic Shares Outstanding | 15.06% | 12.39% | 11.16% | 8.46% | 5.36% |
| Average Diluted Shares Outstanding | 15.06% | 11.78% | 10.55% | 7.86% | 4.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |